1.25
+0.19(+17.92%)
Currency In USD
Address
1601 Trapelo Road
Waltham, MA 02451
United States of America
Phone
781 819 0080
Website
Sector
Healthcare
Industry
Biotechnology
Employees
94
First IPO Date
August 06, 2021
| Name | Title | Pay | Year Born |
| Dr. Robert D. Allen Ph.D. | Chief Scientific Officer | 828,180 | 1969 |
| Ms. Jill Andersen J.D. | Chief Legal Officer & Corporate Secretary | 931,680 | 1973 |
| Mr. Timothy Lee | Chief Commercial Officer | 0 | N/A |
| Scott Young | Senior Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Ms. Stacy Price M.S. | Chief Technology & Manufacturing Officer | 0 | 1969 |
| Mr. William E. Duke Jr., M.B.A. | Chief Financial Officer & Principal Executive Officer | 0 | 1972 |
| Dr. Mark A. Wingertzahn Ph.D. | Senior Vice President of Clinical Development & Medical Affairs | 0 | 1971 |
| Ms. Julie Green M.B.A. | Chief Human Resources Officer | 0 | 1975 |
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.